Vol. 305, Issue 2, 587-592, May 2003
Minneapolis Medical Research Foundation (D.E.K., D.S., M.G.L., P.R.P.);
Hennepin County Medical Center (D.E.K., P.R.P.); Department of Pharmacology,
University of Minnesota Medical School (P.R.P.); College of Pharmacy, University
of Minnesota (D.E.K.); and School of Public Health, University of Minnesota (A.D.C.)
Minneapolis, Minnesota Cigarette smoking during pregnancy is associated with a variety of adverse
fetal outcomes. Nicotine is a likely contributor to these adverse
effects, with fetal brain as one target organ. Vaccination of adult
male rats against nicotine has been shown to reduce nicotine
distribution to the brain. The current study examined whether
vaccination of female rats before pregnancy would reduce the
distribution to fetal brain of a single nicotine dose administered
during gestation. Female rats immunized with a nicotine conjugate
vaccine received a single dose of nicotine 0.03 mg/kg i.v. on
gestational day 16 to 22. Five minutes later, vaccinated rats
had substantially higher bound and lower unbound serum nicotine concentration
and lower brain nicotine concentration than controls. Fetal brain
nicotine concentration was reduced by 43% in vaccinated rats,
comparable to the reduction in the maternal brain nicotine concentration.
The whole-fetus nicotine concentration was not altered by
vaccination. A similar experiment was performed in which pregnant
rats were passively immunized with rabbit nicotine-specific IgG 7 or
21 mg/kg just before nicotine dosing. The effects of passive
immunization on nicotine distribution in the mother were IgG
dose-related and the higher dose reduced nicotine distribution to
fetal brain by 60%. These data suggest that vaccine effects on
nicotine distribution to serum and brain are similar in pregnant female
rats to those previously reported in adult males. Vaccination of
female rats before pregnancy, or passive immunization during pregnancy,
can reduce the exposure of fetal brain to a single dose of maternally
administered nicotine.
筆者へのメールは kaijinhi@yahoo.co.jp にお願いします。
このニコチンワクチンは臨床試験の研究段階です。
このページは商用目的ではありません。